基本情報
| サイトトップ | https://www.heronpharma-sh.com |
|---|
HTMLサイズ
| 1ページ平均HTML（バイト） | 25060.47 |
|---|
内部リンク集計
| リンク総数 | 98 |
|---|
外部リンク集計
| リンク総数 | 7 |
|---|
メタ情報
| meta description平均長 | 129.76 |
|---|---|
| OGPありページ数 | 13 |
| Twitterカードありページ数 | 0 |
HTML言語 分布
| キー | 割合 |
|---|---|
| en | 52.94% |
| ar | 5.88% |
文字コード 分布
| キー | 割合 |
|---|---|
| utf-8 | 100.00% |
内部リンク分析（Internal）
| ユニーク内部リンク数 | 98 |
|---|---|
| ページあたり内部リンク平均 | 37 |
内部リンク 深さヒストグラム
| キー | 値 |
|---|---|
| 0 | 65 |
| 1 | 388 |
| 2 | 168 |
| 3 | 8 |
内部リンク 上位URL
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|---|
| Molecular | 1 |
| Status | 0.748619 |
| Strength | 0.748619 |
| Manufacturer | 0.748619 |
| Name | 0.729882 |
| house | 0.680563 |
| Pharma | 0.660369 |
| Japanese | 0.556101 |
| CAS | 0.556101 |
| Regulatory | 0.541667 |
| Pharmacopoeia | 0.514063 |
| Number | 0.514063 |
| CDMF | 0.514063 |
| Formula | 0.514063 |
| Weight | 0.514063 |
| mol | 0.514063 |
| Clinical | 0.514063 |
| Indications | 0.514063 |
| USP | 0.5 |
| pharmaceutical | 0.359844 |
| Group | 0.340282 |
| sales | 0.272225 |
| China | 0.271594 |
| drugs | 0.257032 |
| was | 0.257032 |
| founded | 0.257032 |
| Heron | 0.225538 |
| Shanghai | 0.209135 |
| our | 0.208538 |
| quality | 0.208333 |
| APIs | 0.208333 |
| excipients | 0.205625 |
| industry | 0.205625 |
| registered | 0.205625 |
| Alfacalcidol | 0.205625 |
| you | 0.205625 |
| CPHI | 0.205625 |
| Our | 0.204169 |
| Nikko | 0.204169 |
| Secondary | 0.204169 |
| hyperparathyroidism | 0.204169 |
| stress | 0.204169 |
| Korea | 0.204169 |
| Date | 0.204169 |
| Location | 0.204169 |
| Calcipotriene | 0.204169 |
| Pharmaceutical | 0.198601 |
| derivatives | 0.173781 |
| Science | 0.168047 |
| Technology | 0.168047 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|---|---|---|
| Japanese | Name | 3.329538 | 64 |
| Science | Technology | 3.275547 | 44 |
| Weight | mol | 3.210437 | 40 |
| Clinical | mol | 3.210437 | 40 |
| Clinical | Indications | 3.210437 | 40 |
| Formula | Molecular | 3.179238 | 50 |
| heronpharma | simon | 3.136854 | 36 |
| com | heronpharma | 3.136854 | 36 |
| CDMF | Number | 3.136628 | 39 |
| Status | house | 3.102986 | 40 |
| Strength | house | 3.102986 | 40 |
| Pharmaceutical | Science | 3.07674 | 44 |
| Ltd | Technology | 3.07674 | 44 |
| Regulatory | Status | 3.07674 | 44 |
| Hunan | Road | 3.017986 | 31 |
| Building | Hunan | 2.869503 | 29 |
| New | Pudong | 2.739585 | 24 |
| Area | District | 2.723938 | 21 |
| Building | Wolicity | 2.715109 | 27 |
| Area | New | 2.713787 | 23 |
| Pudong | Road | 2.697027 | 26 |
| CAS | Number | 2.680564 | 40 |
| Manufacturer | Strength | 2.677131 | 35 |
| Molecular | Weight | 2.547778 | 40 |
| Heron | Pharma | 2.498233 | 69 |
| Formula | Weight | 2.45446 | 30 |
| Clinical | Weight | 2.45446 | 30 |
| Indications | mol | 2.45446 | 30 |
| com | simon | 2.408872 | 27 |
| Hunan | Wolicity | 2.375976 | 24 |
| Area | Pudong | 2.359523 | 21 |
| Status | Strength | 2.345908 | 31 |
| District | New | 2.338778 | 17 |
| Pharmaceutical | Technology | 2.324015 | 33 |
| Ltd | Science | 2.324015 | 33 |
| Characteristic | White | 2.310455 | 12 |
| crystalline | powder | 2.310455 | 12 |
| insoluble | water | 2.310455 | 12 |
| Secondary | hyperparathyroidism | 2.310455 | 12 |
| CAS | Pharmacopoeia | 2.278521 | 34 |
| Wolicity | com | 2.276331 | 24 |
| Pharma | Regulatory | 2.26459 | 40 |
| founded | was | 2.232575 | 16 |
| Regulatory | house | 2.202914 | 30 |
| Building | Road | 2.18103 | 21 |
| high | quality | 2.118583 | 12 |
| New | Road | 2.063704 | 18 |
| March | affiliate | 1.997243 | 8 |
| Nanjing | affiliate | 1.997243 | 8 |
| engaged | producing | 1.997243 | 8 |